Exome Asset Management »

Eli Lilly & Co. shares owned by Exome Asset Management

Quarter-by-quarter ownership of Eli Lilly & Co. (LLY) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Eli Lilly & Co.

Tip: Access up to 7 years of quarterly data

All positions including Eli Lilly & Co. held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eli Lilly & Co. by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $5.7M 9.7k 582.92

More positions owned by Exome Asset Management

Dr Reddys Labs Adr (RDY)
Eli Lilly & Co. (LLY)
ImmunoGen
Cigna Corp (CI)
Celldex Therapeutics Com New (CLDX)
Tg Therapeutics (TGTX)
Rhythm Pharmaceuticals (RYTM)
Alpine Immune Sciences (ALPN)
Dex (DXCM)
Madrigal Pharmaceuticals (MDGL)
Cytokinetics Com New (CYTK)
Inhibrx (INBX)
Structure Therapeutics Sponsored Ads (GPCR)
Rocket Pharmaceuticals (RCKT)
Bridgebio Pharma (BBIO)

View all positions for Exome Asset Management

Top funds holding Eli Lilly & Co.

Lilly Endowment
Vanguard Group
Pnc Financial Services
PRIMECAP Management Company
T. Rowe Price Associates
Jpmorgan Chase & Co
State Farm Mutual Automobile Insurance Company
Wellington Management Company
Bank of America Corporation
Norges Bank Investment Management
Jennison Associates
Legal & General Group
Bank of New York Mellon
Alliancebernstein
Goldman Sachs Group

View all funds holding Eli Lilly & Co.